BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 10,321 Shares of IQVIA Holdings Inc. (NYSE:IQV)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,498 shares of the medical research company's stock after selling 10,321 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.06% of IQVIA worth $23,815,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in IQVIA during the third quarter worth about $147,683,000. 1832 Asset Management L.P. boosted its stake in shares of IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after purchasing an additional 376,595 shares during the period. Renaissance Technologies LLC purchased a new position in shares of IQVIA in the second quarter valued at approximately $70,610,000. Impax Asset Management Group plc boosted its stake in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock valued at $344,998,000 after purchasing an additional 264,555 shares during the period. Finally, Canada Pension Plan Investment Board raised its holdings in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock valued at $719,634,000 after acquiring an additional 211,653 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company's stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Up 2.1 %

Shares of IQV traded up $4.22 during midday trading on Friday, reaching $201.82. 1,887,846 shares of the stock were exchanged, compared to its average volume of 2,206,617. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a 50 day simple moving average of $222.67 and a 200-day simple moving average of $227.18. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $36.63 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 2.03 and a beta of 1.51.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on IQV shares. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a report on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 5th. Morgan Stanley lowered their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Barclays lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, Robert W. Baird decreased their target price on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.